HLS Therapeutics (TSE:HLS) Stock Price Down 0.2% – What’s Next?

Shares of HLS Therapeutics Inc. (TSE:HLS) dropped 0.2% during trading on Monday . The company traded as low as C$4.39 and last traded at C$4.39. Approximately 223 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 9,278 shares. The stock had previously closed at C$4.40.

HLS Therapeutics Price Performance

The company has a quick ratio of 1.01, a current ratio of 1.11 and a debt-to-equity ratio of 80.79. The stock has a market capitalization of C$136.67 million, a price-to-earnings ratio of -11.21 and a beta of 0.34. The business’s 50 day simple moving average is C$4.44 and its 200-day simple moving average is C$4.88.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Thursday, March 12th. The company reported C($0.05) EPS for the quarter. The firm had revenue of C$20.06 million during the quarter. HLS Therapeutics had a negative net margin of 22.34% and a negative return on equity of 19.40%. On average, research analysts forecast that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.